Médecins Sans Frontières & Moderna

Médecins Sans Frontières: Frontline medical charity warning of alarming spread, facing operational challenges and attacks. Its capacity is stretched, affecting its ability to respond.

Moderna: Authorized to begin Phase 1 trials for a Bundibugyo vaccine, using mRNA technology. Potential for significant revenue if successful.

Médecins Sans Frontières: Médecins Sans Frontières (MSF) has warned that the Ebola outbreak is spreading faster than the response, calling for immediate expansion of testing, faster deployment of aid workers, and sustained access for medical supplies.

Moderna: Moderna is utilizing its mRNA technology to develop a vaccine for the Bundibugyo strain of Ebola, with funding from CEPI, aiming to rapidly train the body to fight the virus.

Médecins Sans Frontières: Providing frontline medical care and warning the outbreak is spreading at an 'alarming and unprecedented rate'. Its operations are vital in affected areas.

Moderna: Developed an mRNA-based Bundibugyo vaccine candidate, with Phase 1 trials starting in Canada. Its mRNA platform could offer a rapid response to emerging outbreaks.

Médecins Sans Frontières: Médecins Sans Frontières (Doctors Without Borders) is actively responding to the Ebola outbreak, highlighting the worsening insecurity and catastrophic hygiene conditions in displacement sites.

Moderna: Moderna is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.

Médecins Sans Frontières: Médecins Sans Frontières is providing frontline care and warning of insufficient support, underscoring the humanitarian crisis. Its operations are vital but strained.

Moderna: Moderna is developing an mRNA-based vaccine targeting the Bundibugyo strain, currently in clinical trials. Its progress could offer a more specific solution and enhance its vaccine portfolio.

Médecins Sans Frontières: Médecins Sans Frontières (Doctors Without Borders) teams have identified suspected Ebola cases in Bunia hospitals, but found no available isolation wards, illustrating the overwhelmed healthcare infrastructure.

Moderna: Moderna is one of the entities developing an experimental vaccine for the Bundibugyo virus, which could lead to future revenue and enhance its reputation in vaccine development.